Quinupristin/dalfopristin - Revision history

Danbot: Add See Also section

2026-03-22T09:14:31Z

Add See Also section

← Older revision		Revision as of 09:14, 22 March 2026
Line 165:		Line 165:
	===Key===		===Key===
	{{Template:Antibacterial Spectra Key}}		{{Template:Antibacterial Spectra Key}}

			==See Also==
			*[[Antibiotics]]
			*[[MRSA]]
			*[[Vancomycin]]

	==References==		==References==

ClaireLewis at 22:14, 23 September 2019

2019-09-23T22:14:05Z

@@ Line 1: / Line 1: @@
 ==Uses==
-*Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)
+*[[Antibiotic]]: treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)
 ==Administration==
@@ Line 44: / Line 44: @@
 *Excretion:
 ==References==
@@ Line 49: / Line 170: @@
 *2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf
 [[Category:Pharmacology]]

Neil.m.young: Text replacement - "pruritis" to "pruritus"

2016-10-27T17:16:34Z

Text replacement - "pruritis" to "pruritus"

← Older revision		Revision as of 17:16, 27 October 2016
Line 37:		Line 37:
	*rash		*rash
	*headache		*headache
	*~~pruritis~~		*pruritus

	==Pharmacology==		==Pharmacology==

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-20T23:59:53Z

Text replacement - "5 mg" to "5mg"

← Older revision		Revision as of 23:59, 20 July 2016
Line 8:		Line 8:

	==Adult Dosing==		==Adult Dosing==
	*VRE: 7.~~5 mg~~/kg IV q8 hrs for minimum 7 days		*VRE: 7.5mg/kg IV q8 hrs for minimum 7 days
	*skin infections: 7.~~5 mg~~/kg IV q12 hrs for minimum 7 days		*skin infections: 7.5mg/kg IV q12 hrs for minimum 7 days

	==Pediatric Dosing==		==Pediatric Dosing==

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-20T14:22:47Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 14:22, 20 July 2016
Line 3:		Line 3:

	==Administration==		==Administration==
	*Dosage Forms: ~~500 mg~~ vials, diluted into 250 mL and given over 60 mins		*Dosage Forms: 500mg vials, diluted into 250 mL and given over 60 mins
	*Routes of Administration: IV		*Routes of Administration: IV
	*Common Trade Names: Synercid		*Common Trade Names: Synercid

Neil.m.young: Text replacement - "* " to "*"

2016-07-06T11:59:39Z

Text replacement - "* " to "*"

← Older revision		Revision as of 11:59, 6 July 2016
Line 1:		Line 1:
	==Uses==		==Uses==
	* Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)		*Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)

	==Administration==		==Administration==
Line 8:		Line 8:

	==Adult Dosing==		==Adult Dosing==
	* VRE: 7.5 mg/kg IV q8 hrs for minimum 7 days		*VRE: 7.5 mg/kg IV q8 hrs for minimum 7 days
	* skin infections: 7.5 mg/kg IV q12 hrs for minimum 7 days		*skin infections: 7.5 mg/kg IV q12 hrs for minimum 7 days

	==Pediatric Dosing==		==Pediatric Dosing==
	* safety and efficacy has not been studied in children		*safety and efficacy has not been studied in children

	==Special Populations==		==Special Populations==
Line 19:		Line 19:

	===Renal Dosing===		===Renal Dosing===
	* no adjustments for renal impairment		*no adjustments for renal impairment

	===Hepatic Dosing===		===Hepatic Dosing===
	* dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)		*dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)


Line 32:		Line 32:

	===Common===		===Common===
	* pain and inflammation at infusion site		*pain and inflammation at infusion site
	*arthralgias		*arthralgias
	*nausea/vomiting/diarrhea		*nausea/vomiting/diarrhea

Ostermayer: Text replacement - "Category:Drugs" to "Category:Pharmacology"

2016-03-22T15:53:54Z

Text replacement - "Category:Drugs" to "Category:Pharmacology"

← Older revision		Revision as of 15:53, 22 March 2016
Line 48:		Line 48:
	*1. JP Manzanella. "Quinupristin-Dalfopristin: A New Antibiotic for Severe Gram-Positive Infections." American Family Physician. 2001 Dec 1;64(11):1863-1867.		*1. JP Manzanella. "Quinupristin-Dalfopristin: A New Antibiotic for Severe Gram-Positive Infections." American Family Physician. 2001 Dec 1;64(11):1863-1867.
	*2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf		*2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf
	[[Category:~~Drugs~~]]		[[Category:Pharmacology]]

NicoleZadzilka: Created page with "==Uses== * Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1) ==Administration== *Dosage Fo..."

2016-01-15T15:13:46Z

Created page with "==Uses== * Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1) ==Administration== *Dosage Fo..."

New page

==Uses==
* Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)

==Administration==
*Dosage Forms: 500 mg vials, diluted into 250 mL and given over 60 mins
*Routes of Administration: IV
*Common Trade Names: Synercid

==Adult Dosing==
* VRE: 7.5 mg/kg IV q8 hrs for minimum 7 days
* skin infections: 7.5 mg/kg IV q12 hrs for minimum 7 days

==Pediatric Dosing==
* safety and efficacy has not been studied in children

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*[[Lactation risk categories|Lactation risk]]: unknown whether secreted in human breast milk. Caution should be exercised when administering to nursing mothers. (2)

===Renal Dosing===
* no adjustments for renal impairment

===Hepatic Dosing===
* dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)

==Contraindications==
*Allergy to class/drug

==Adverse Reactions==
===Serious===

===Common===
* pain and inflammation at infusion site
*arthralgias
*nausea/vomiting/diarrhea
*rash
*headache
*pruritis

==Pharmacology==
*Half-life: Quinupristin: 3 hrs; Dalfopristin: 1 hr
*Metabolism: significantly interacts with the CYP 3A4 system.
*Excretion:

==References==
*1. JP Manzanella. "Quinupristin-Dalfopristin: A New Antibiotic for Severe Gram-Positive Infections." American Family Physician. 2001 Dec 1;64(11):1863-1867.
*2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf
[[Category:Drugs]]